Saibo Co., Ltd. (3123) AI Stock Analysis

• Market Cap: ¥6.80B
• Dividend Yield: 3.01%
• Average Volume (3M): 9.31K
• Price to Earnings (P/E): 8.9
• Beta (1Y): 0.41
• Revenue Growth: -5.12%
• EPS Growth: -24.98%
• Country: JP
• Employees: 115
• Sector: Consumer Cyclical
• Sector Strength: 73
• Industry: Apparel - Manufacturers
• EPS (TTM): 22.22
• Shares Outstanding: 13,600,000
• 10 Day Avg. Volume: 9,620
• 30 Day Avg. Volume: 9,306
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ¥614.00
• Price Target Upside: 15.41% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 79 Outperform
• Price Target: ¥614.00 ▲(15.41% Upside)

Saibo Co., Ltd. receives a strong overall score due to its robust financial performance and attractive valuation. The stock's technical indicators suggest bullish momentum, further supporting a positive outlook. The absence of earnings call data and corporate events does not detract from the company's solid fundamentals and market position.

Saibo Co., Ltd. Business Overview & Revenue Model

Company Description

Saibo Co., Ltd. (3123) is a prominent player in the biotechnology and pharmaceutical sectors, specializing in the research, development, and manufacturing of innovative healthcare products. The company focuses on biopharmaceuticals, diagnostics, and medical devices, aiming to improve patient outcomes through advanced technology and scientific research. With a commitment to quality and innovation, Saibo Co., Ltd. serves a global market, providing solutions that address various medical needs.

How the Company Makes Money

Saibo Co., Ltd. generates revenue primarily through the sale of its biopharmaceutical products, which include therapeutics and vaccines. The company also earns income from diagnostic tools and medical devices that are utilized in healthcare settings. Additionally, Saibo Co., Ltd. engages in strategic partnerships and collaborations with research institutions and other biotech firms, which often lead to joint ventures and co-development agreements, further enhancing its revenue streams. Licensing agreements for its proprietary technologies and products also contribute significantly to its earnings. The company's focus on innovation and adherence to regulatory standards positions it favorably in the competitive biotech landscape, allowing for sustained revenue growth.

Saibo Co., Ltd. Financial Statement Overview

Summary

Saibo Co., Ltd. has demonstrated consistent revenue growth and strong operational efficiency, reflected in its income statement score. However, the balance sheet and cash flow statements highlight concerns with leverage and inconsistent free cash flow, which could affect financial stability.

Income Statement

Saibo Co., Ltd. has demonstrated consistent revenue growth over the years, with a noticeable recovery in gross profit margin following a dip in the previous year. The net profit margin has shown resilience, reflecting efficient cost management despite fluctuations in EBIT. The company's EBITDA margin remains strong, indicating solid operational performance.

Balance Sheet

The balance sheet shows a moderate debt-to-equity ratio, suggesting a balanced approach to leverage. The return on equity has remained healthy, highlighting effective use of shareholder funds. However, the equity ratio indicates a potential risk with a significant portion of assets financed by liabilities.

Cash Flow

While operating cash flow has been stable, the free cash flow growth rate is inconsistent, influenced by varying capital expenditures. The company maintains a positive operating cash flow to net income ratio, but the high variability in free cash flow suggests potential issues with capital investment strategies.

Breakdown	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	10.30B	11.42B	10.18B	8.96B	6.73B
Gross Profit	2.70B	2.64B	2.40B	1.86B	1.96B
EBITDA	2.71B	2.92B	2.61B	2.20B	1.52B
Net Income	859.55M	945.72M	733.21M	499.59M	587.76M
Balance Sheet
Total Assets	41.95B	43.53B	41.85B	42.90B	39.13B
Cash, Cash Equivalents and Short-Term Investments	3.95B	3.64B	2.99B	2.59B	1.82B
Total Debt	12.88B	14.00B	15.07B	16.75B	14.80B
Total Liabilities	21.82B	23.97B	23.67B	25.41B	22.52B
Stockholders Equity	17.74B	17.20B	15.97B	15.33B	14.51B
Cash Flow
Free Cash Flow	1.95B	1.94B	1.93B	-1.06B	-10.07B
Operating Cash Flow	2.37B	2.27B	2.30B	2.04B	2.14B
Investing Cash Flow	-627.31M	-165.85M	-147.64M	-2.98B	-12.14B
Financing Cash Flow	-1.48B	-1.37B	-1.90B	1.74B	10.07B

Saibo Co., Ltd. Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 532.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:3123, the sentiment is Neutral. The current price of 532 is below the 20-day moving average (MA) of 533.60, above the 50-day MA of 512.00, and above the 200-day MA of 477.72, indicating a neutral trend. The MACD of 5.32 indicates Positive momentum. The RSI at 54.24 is Neutral, neither overbought nor oversold. The STOCH value of 43.48 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for JP:3123.

Saibo Co., Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
3123	79 Outperform	¥6.80B	8.91		3.01%	-5.12%	-24.98%
3104	77 Outperform	¥68.34B	14.31		2.09%	15.29%	87.17%
3201	74 Outperform	¥91.66B	11.27		2.84%	7.01%	11.28%
3580	69 Neutral	¥32.25B	12.06		3.25%	7.46%	1.54%
3109	66 Neutral	¥12.72B	14.50		4.87%	1.93%	-1.93%
Sector *	61 Neutral	$17.43B	12.62	-6.02%	3.11%	1.71%	-15.47%
3409	51 Neutral	¥5.79B	―		―	24.79%	56.47%